产品
编 号：F439011
分子式：C14H10N4O5
分子量：314.25
分子式：C14H10N4O5
分子量：314.25
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 7261-97-4
产品详情
生物活性：
Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
体内研究：
Dantrolene (5 mg/kg；每周口服两次)可改善平衡木行走和步态行走测定中的表现。 Dantrolene (10mg/kg；腹腔；每周三天；持续 40-60 天）可显着改善步态，降低 LC3-II 水平，改善线粒体 ATP 生成并减少大脑炎症。Dantrolene 降低神经病性戈谢病小鼠大脑中的自噬和 CALM (钙调蛋白)的表达。 Animal Model:YAC128 transgenic mice (FVBN/NJ background strain) and WT mice
Dosage:5 mg/kg
Administration:Fed orally twice per week from 2 to 11.5 months of age
Result:Resulted in significantly improved performance in the beam-walking and gait-walking assays. Significantly reduced the loss of NeuN-positive striatal neurons and reduced formation of Httexp nuclear aggregates.
体外研究：
Dantrolene (60 μM；第 1 天和第 3 天) 显着抑制 paVIC 中的 ACTA2 表达并上调 RUNX2 表达。 Dantrolene (60 μM；过夜预处理) 可抑制猪主动脉瓣间质细胞中 LPC 诱导的钙流。Dantrolene (10、30、60 μM) 可抑制 10 μM 溶血磷脂酰胆碱 (LPC) 引起的 paVIC 钙化结节的形成。
Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
体内研究：
Dantrolene (5 mg/kg；每周口服两次)可改善平衡木行走和步态行走测定中的表现。 Dantrolene (10mg/kg；腹腔；每周三天；持续 40-60 天）可显着改善步态，降低 LC3-II 水平，改善线粒体 ATP 生成并减少大脑炎症。Dantrolene 降低神经病性戈谢病小鼠大脑中的自噬和 CALM (钙调蛋白)的表达。 Animal Model:YAC128 transgenic mice (FVBN/NJ background strain) and WT mice
Dosage:5 mg/kg
Administration:Fed orally twice per week from 2 to 11.5 months of age
Result:Resulted in significantly improved performance in the beam-walking and gait-walking assays. Significantly reduced the loss of NeuN-positive striatal neurons and reduced formation of Httexp nuclear aggregates.
体外研究：
Dantrolene (60 μM；第 1 天和第 3 天) 显着抑制 paVIC 中的 ACTA2 表达并上调 RUNX2 表达。 Dantrolene (60 μM；过夜预处理) 可抑制猪主动脉瓣间质细胞中 LPC 诱导的钙流。Dantrolene (10、30、60 μM) 可抑制 10 μM 溶血磷脂酰胆碱 (LPC) 引起的 paVIC 钙化结节的形成。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备